Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Finalizes Labeling Rule As Pre-emption Battle At Supreme Court Looms

This article was originally published in The Pink Sheet Daily

Executive Summary

January’s proposed rule remains mostly unchanged, but the definition of “newly acquired information” is slightly broader now.

You may also be interested in...



Pre-emption Rule Delays Safety-related Label Changes, Waxman Charges

An FDA rule that requires the agency to approve labeling changes before they can be made has delayed the addition of safety information to at least two products, according to a report from Rep. Henry Waxman, D-Calif

Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case

This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation

Pre-emption Rule Delays Safety-related Label Changes, Waxman Charges

An FDA rule that requires the agency to approve labeling changes before they can be made has delayed the addition of safety information to at least two products, according to a report from Rep. Henry Waxman, D-Calif

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel